A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

BackgroundCLEC5A is a member of the C-type lectin superfamily. It can activate macrophages and lead to a series of immune-inflammation reactions. Previous studies reveal the role of CLEC5A in infection and inflammation diseases.MethodWe acquire and analyze data from The Cancer Genome Atlas (TCGA) da...

Full description

Bibliographic Details
Main Authors:	Rui Chen, Wantao Wu, Si-Yu Chen, Zheng-Zheng Liu, Zhi-Peng Wen, Jing Yu, Long-Bo Zhang, Zaoqu Liu, Jian Zhang, Peng Luo, Wen-Jing Zeng, Quan Cheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Immunology
Subjects:	pan-cancer CLEC5A prognostic biomarkers cancer immune immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.831542/full

Similar Items

Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets
by: Aiyuan Guo, et al.
Published: (2022-10-01)

Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy
by: Yu Chen, et al.
Published: (2022-08-01)

Identification and characterization of CLEC11A and its derived immune signature in gastric cancer
by: Qing Zheng, et al.
Published: (2024-01-01)

Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer
by: Jingwei Zhang, et al.
Published: (2022-04-01)

A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy
by: He Li, et al.
Published: (2022-12-01)

CLEC4E upregulation in gastric cancer: A potential therapeutic target correlating with tumor-associated macrophages
by: Qin Jiang, et al.
Published: (2024-03-01)

Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance
by: Kun Zheng, et al.
Published: (2023-11-01)

<i>EGFR</i> Mutation-Harboring Lung Cancer Cells Produce CLEC11A with Endothelial Trophic and Tumor-Promoting Activities
by: Tzu-Yin Lin, et al.
Published: (2022-03-01)

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment
by: Jiaxing Sun, et al.
Published: (2020-04-01)

CLEC2 and CLEC5A: Pathogenic Host Factors in Acute Viral Infections
by: Pei-Shan Sung, et al.
Published: (2019-12-01)

Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A
by: M. H. Lahoud, et al.
Published: (2022-01-01)

CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation
by: Pei-Shan Sung, et al.
Published: (2022-07-01)

CLEC5A mediates Zika virus-induced testicular damage
by: Hsin-Wei Wang, et al.
Published: (2023-02-01)

In-Silico CLEC5A mRNA expression analysis to predict Dengue susceptibility in cancer patients
by: Surabhi Suchanti, et al.
Published: (2023-09-01)

The Role of CLEC-2 and Its Ligands in Thromboinflammation
by: Danyang Meng, et al.
Published: (2021-06-01)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
by: Hao Zhang, et al.
Published: (2021-06-01)

Clinical Implications of Necroptosis Genes Expression for Cancer Immunity and Prognosis: A Pan-Cancer Analysis
by: Xin-yu Li, et al.
Published: (2022-06-01)

Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma
by: Qiangan Jing, et al.
Published: (2023-06-01)

Correlation of CLEC1B haplotypes with plasma levels of soluble CLEC-2 in healthy individuals
by: Mani Etemad, et al.
Published: (2021-11-01)

Roles of the CLEC-2–podoplanin interaction in tumor progression
by: Katsue Suzuki-Inoue
Published: (2018-11-01)

CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of artemisinin by repressing autophagy and inflammation
by: Ranodeep Chatterjee, et al.
Published: (2023-12-01)

CLEC11A expression as a prognostic biomarker in correlation to immune cells of gastric cancer
by: Weidan Fang, et al.
Published: (2024-01-01)

Human rs75776403 polymorphism links differential phenotypic and clinical outcomes to a CLEC18A p.T151M-driven multiomics
by: Yu-Wen Hsu, et al.
Published: (2022-06-01)

Corrigendum: CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of artemisinin by repressing autophagy and inflammation
by: Ranodeep Chatterjee, et al.
Published: (2024-03-01)

Identification of an Immune-Related Prognostic Gene CLEC5A Based on Immune Microenvironment and Risk Modeling of Ovarian Cancer
by: Jiacheng Shen, et al.
Published: (2021-10-01)

Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy
by: Qinfei Zhao, et al.
Published: (2022-07-01)

Molecular Analysis of the Interaction of the Snake Venom Rhodocytin with the Platelet Receptor CLEC-2
by: Christopher A. O’Callaghan, et al.
Published: (2011-08-01)

Screening Dys-Methylation Genes and Rules for Cancer Diagnosis by Using the Pan-Cancer Study
by: Yu-Hang Zhang, et al.
Published: (2020-01-01)

Downregulation of exosomal CLEC3B in hepatocellular carcinoma promotes metastasis and angiogenesis via AMPK and VEGF signals
by: Wenjuan Dai, et al.
Published: (2019-09-01)

Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer
by: HanZheng Zhao, et al.
Published: (2022-08-01)

Soluble CLEC2 Extracellular Domain Improves Glucose and Lipid Homeostasis by Regulating Liver Kupffer Cell Polarization
by: Xinle Wu, et al.
Published: (2015-03-01)

Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis
by: Yuanyuan Liu, et al.
Published: (2022-04-01)

Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment
by: Byeong-Oh Hwang, et al.
Published: (2021-12-01)

High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia
by: Chengliang Yin, et al.
Published: (2021-03-01)

Low Expression of CLEC2B Indicates Poor Prognosis in Melanoma
by: Zhang Y, et al.
Published: (2023-02-01)

Comprehensive analysis indicated that NDE1 is a potential biomarker for pan‐cancer and promotes bladder cancer progression
by: Peihan Wang, et al.
Published: (2024-03-01)

CLEC-2 Prevents Accumulation and Retention of Inflammatory Macrophages During Murine Peritonitis
by: Joshua H. Bourne, et al.
Published: (2021-06-01)

Lymphatic blood filling in CLEC-2-deficient mouse models
by: Elizabeth J Haining, et al.
Published: (2021-04-01)

Platelet CLEC‐2 and lung development
by: Katsue Suzuki‐Inoue, et al.
Published: (2020-05-01)

CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment
by: Yinjiang Zhang, et al.
Published: (2021-08-01)